Population pharmacokinetics and pharmacodynamics of<scp>BYL</scp>719, a phosphoinositide 3‐kinase antagonist, in adult patients with advanced solid malignancies

Abstract

The proposed model provides a valuable approach for planning future clinical studies and for designing optimized dosing regimens with BYL719.